This article has been updated to clarify Exosome's partnerships.

Exosome Diagnostics is exploring next-generation sequencing as a potential platform for diagnostic tests for cancer and other diseases in biofluids.

The company was founded in 2008 around exosome technology it exclusively licensed from Massachusetts General Hospital. While Exosome currently focuses on developing qPCR-based diagnostics for prostate and brain cancer, it has also been investigating next-gen sequencing and recently brought in the Illumina MiSeq platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.